3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
6
Neuroendocrine Tumors
2
Gastro-enteropancreatic neuroendocrine tumor
2
Digestive System Neoplasms
2
Urogenital Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Oligometastatic Prostate Cancer (OMPC)
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Metastatic Castration-Resistant Prostate Cancer
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Diseases
1
Breast Neoplasms
1
Advanced Gastroenteropancreatic Neuroendocrine Tumor
1
Interventions
enzalutamide
4
Docetaxel
2
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
abiraterone
1
Prednisone
1
PF06821497
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-Resistant Prostate Cancer
×
Lutetium-177
×
Clear all
NCT06531499
2025-12-31
RADIODOSE
Novartis
Phase 1
Recruiting
106 enrolled